Literature DB >> 32260162

Relationship between 2-Hour Tacrolimus Concentrations and Clinical Outcomes in Long Term Kidney Transplantation.

Jeffrey Yin1, Tammy Hsu2, Janice S Kerr1, Robert Steiner3, Linda Awdishu2.   

Abstract

Background: Tacrolimus is routinely monitored using trough concentrations, however, recent data have suggested that area under the curve (AUC) provides better correlation with toxicity and efficacy. Area under the curve is cumbersome to measure, but studies have demonstrated that surrogate time points such as 2-hour concentrations are well correlated with AUC.
Methods: This is a single center, retrospective study of adult kidney transplant recipients with 2-hour tacrolimus concentrations measured over three years post-transplant. The primary outcome was to determine the difference in serum creatinine (Scr) in those with 2-hour tacrolimus concentrations greater than 20 ng/mL versus those less than or equal to 20 ng/mL.
Results: A total of 150 kidney transplant recipients were included. The mean Scr and glomerular filtration rate were 1.49 ± 1.01 mg/dL and 59 ± 23.2 ml/min/1.73 m2, respectively, for the entire cohort. The rate of donor specific antibody formation was 2% and 8% experienced biopsy-proven rejection. The rate of cytomegalovirus viremia was 2% and BK viremia was 13%. There was no significant difference in kidney function over 36 months for the groups specified a priori. Conclusions: Long-term outcomes of maintaining tacrolimus 2-hour concentrations over 20 ng/mL is favorable with minimal opportunistic infections.

Entities:  

Keywords:  drug monitoring; kidney transplantation; tacrolimus

Year:  2020        PMID: 32260162     DOI: 10.3390/pharmacy8020060

Source DB:  PubMed          Journal:  Pharmacy (Basel)        ISSN: 2226-4787


  1 in total

1.  Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.

Authors:  Victoria G Hall; Victor Ferreira; Deepali Kumar; Atul Humar
Journal:  Transpl Infect Dis       Date:  2021-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.